Journal of Clinical Trials
Open Access

David Rizzieri

Biography

As a translational researcher, he has focused his efforts on developing new therapies for patients with leukemia or lymphoma. He has been a member of the Combined International Bone Marrow Transplant Registry Lymphoma Writing Committee and is a member of the ALLIANCE (formerly CALGB) Leukemia Core Committee. He has served as chair or co-chair of multiple ALLIANCE lymphoma/ leukemia trials. He has led a team’s novel approaches for the care of patients using non-myeloablative allogeneic therapy to optimize a less toxic regimen for transplant of patients with hematologic malignancies using haplo-identical, as well as matched donors. This work is currently being extended with post-transplant graft manipulation studies focused on manipulating Natural Killer cell activity. He has led the development of anti-stromal therapy in lymphoma using new antibodies targeting the stromal protein, tenascin, and other early stage clinical studies. Further, He has served on various NIH/NHLBI grant review committees and the ASH sub-committee on Government Affairs. He oversees the development and conduct of all clinical trials in adults with hematologic malignancies conducted in the Duke Cancer Institute. In recognition of this leadership and success in our clinical research efforts, he was fortunate to receive the NIH ‘Clinical Investigator Team Leadership Award’ in 2010 and was awarded by the fellows the ‘Wendell Rosse Teaching Award’ in 2009.

Research Interest

Leukemia
Lymphoma
Hematologic malignancies